Cargando…

Regular Supplementation With Resveratrol Improves Bone Mineral Density in Postmenopausal Women: A Randomized, Placebo‐Controlled Trial

Resveratrol, a naturally occurring polyphenol in red grapes and berries, can act as a phytoestrogen. It has been shown to improve both systemic and cerebral circulatory functions, possibly through activation of endothelial estrogen receptors. in vitro and in vivo studies in rodent models also indica...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Rachel HX, Thaung Zaw, Jay Jay, Xian, Cory J, Howe, Peter RC
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689937/
https://www.ncbi.nlm.nih.gov/pubmed/32564438
http://dx.doi.org/10.1002/jbmr.4115
_version_ 1783613965185581056
author Wong, Rachel HX
Thaung Zaw, Jay Jay
Xian, Cory J
Howe, Peter RC
author_facet Wong, Rachel HX
Thaung Zaw, Jay Jay
Xian, Cory J
Howe, Peter RC
author_sort Wong, Rachel HX
collection PubMed
description Resveratrol, a naturally occurring polyphenol in red grapes and berries, can act as a phytoestrogen. It has been shown to improve both systemic and cerebral circulatory functions, possibly through activation of endothelial estrogen receptors. in vitro and in vivo studies in rodent models also indicate a bone‐protective role for resveratrol, particularly in ovariectomized rat models that mimic postmenopausal osteoporosis caused by estrogen deficiency. Hypothesizing a circulatory benefit of resveratrol in bone tissue, we investigated whether resveratrol supplementation could improve bone health in postmenopausal women. The Resveratrol for Healthy Aging in Women (RESHAW) trial was a 24‐month randomized, double‐blind, placebo‐controlled, two‐period crossover intervention conducted to evaluate the effects of resveratrol (75 mg twice daily) on cognition, cerebrovascular function, bone health, cardiometabolic markers, and well‐being in postmenopausal women. After 12 months of supplementation with resveratrol versus placebo, there were positive effects on bone density in the lumbar spine (+0.016 ± 0.003 g/cm(2)) and neck of femur (+0.005 ± 0.002 g/cm(2)), which were accompanied by a 7.24% reduction in C‐terminal telopeptide type‐1 collagen levels, a bone resorption marker, compared with placebo. The increase in bone mineral density in the femoral neck resulted in an improvement in T‐score (+0.070 ± 0.018) and a reduction in the 10‐year probability of major and hip fracture risk. The magnitude of improvement was higher in women with poor bone health biomarker status. Importantly, the improvement in femoral neck T‐score with resveratrol correlated with improvement in perfusion. Our subanalysis also revealed that the bone‐protective benefit of resveratrol was greater in participants who supplemented with vitamin D plus calcium. Regular supplementation with 75 mg of resveratrol twice daily has the potential to slow bone loss in the lumbar spine and femoral neck, common fracture sites in postmenopausal women without overt osteoporosis. © 2020 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research.
format Online
Article
Text
id pubmed-7689937
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-76899372020-12-08 Regular Supplementation With Resveratrol Improves Bone Mineral Density in Postmenopausal Women: A Randomized, Placebo‐Controlled Trial Wong, Rachel HX Thaung Zaw, Jay Jay Xian, Cory J Howe, Peter RC J Bone Miner Res Clinical Trial Resveratrol, a naturally occurring polyphenol in red grapes and berries, can act as a phytoestrogen. It has been shown to improve both systemic and cerebral circulatory functions, possibly through activation of endothelial estrogen receptors. in vitro and in vivo studies in rodent models also indicate a bone‐protective role for resveratrol, particularly in ovariectomized rat models that mimic postmenopausal osteoporosis caused by estrogen deficiency. Hypothesizing a circulatory benefit of resveratrol in bone tissue, we investigated whether resveratrol supplementation could improve bone health in postmenopausal women. The Resveratrol for Healthy Aging in Women (RESHAW) trial was a 24‐month randomized, double‐blind, placebo‐controlled, two‐period crossover intervention conducted to evaluate the effects of resveratrol (75 mg twice daily) on cognition, cerebrovascular function, bone health, cardiometabolic markers, and well‐being in postmenopausal women. After 12 months of supplementation with resveratrol versus placebo, there were positive effects on bone density in the lumbar spine (+0.016 ± 0.003 g/cm(2)) and neck of femur (+0.005 ± 0.002 g/cm(2)), which were accompanied by a 7.24% reduction in C‐terminal telopeptide type‐1 collagen levels, a bone resorption marker, compared with placebo. The increase in bone mineral density in the femoral neck resulted in an improvement in T‐score (+0.070 ± 0.018) and a reduction in the 10‐year probability of major and hip fracture risk. The magnitude of improvement was higher in women with poor bone health biomarker status. Importantly, the improvement in femoral neck T‐score with resveratrol correlated with improvement in perfusion. Our subanalysis also revealed that the bone‐protective benefit of resveratrol was greater in participants who supplemented with vitamin D plus calcium. Regular supplementation with 75 mg of resveratrol twice daily has the potential to slow bone loss in the lumbar spine and femoral neck, common fracture sites in postmenopausal women without overt osteoporosis. © 2020 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research. John Wiley & Sons, Inc. 2020-07-14 2020-11 /pmc/articles/PMC7689937/ /pubmed/32564438 http://dx.doi.org/10.1002/jbmr.4115 Text en © 2020 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Trial
Wong, Rachel HX
Thaung Zaw, Jay Jay
Xian, Cory J
Howe, Peter RC
Regular Supplementation With Resveratrol Improves Bone Mineral Density in Postmenopausal Women: A Randomized, Placebo‐Controlled Trial
title Regular Supplementation With Resveratrol Improves Bone Mineral Density in Postmenopausal Women: A Randomized, Placebo‐Controlled Trial
title_full Regular Supplementation With Resveratrol Improves Bone Mineral Density in Postmenopausal Women: A Randomized, Placebo‐Controlled Trial
title_fullStr Regular Supplementation With Resveratrol Improves Bone Mineral Density in Postmenopausal Women: A Randomized, Placebo‐Controlled Trial
title_full_unstemmed Regular Supplementation With Resveratrol Improves Bone Mineral Density in Postmenopausal Women: A Randomized, Placebo‐Controlled Trial
title_short Regular Supplementation With Resveratrol Improves Bone Mineral Density in Postmenopausal Women: A Randomized, Placebo‐Controlled Trial
title_sort regular supplementation with resveratrol improves bone mineral density in postmenopausal women: a randomized, placebo‐controlled trial
topic Clinical Trial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689937/
https://www.ncbi.nlm.nih.gov/pubmed/32564438
http://dx.doi.org/10.1002/jbmr.4115
work_keys_str_mv AT wongrachelhx regularsupplementationwithresveratrolimprovesbonemineraldensityinpostmenopausalwomenarandomizedplacebocontrolledtrial
AT thaungzawjayjay regularsupplementationwithresveratrolimprovesbonemineraldensityinpostmenopausalwomenarandomizedplacebocontrolledtrial
AT xiancoryj regularsupplementationwithresveratrolimprovesbonemineraldensityinpostmenopausalwomenarandomizedplacebocontrolledtrial
AT howepeterrc regularsupplementationwithresveratrolimprovesbonemineraldensityinpostmenopausalwomenarandomizedplacebocontrolledtrial